Xeris Biopharma Holdings Inc (XERS)
R&D to Revenue
11.58%
Quarterly · Period ending:
XERS R&D to Revenue
Latest reported11.58%period ending
Latest reported11.58%period ending
XERS Quarterly R&D/Revenue (1034.46% → 11.58%)
Latest values, visible window
High-resolution chart · PNG
XERS r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 11.5841% | |
| 10.5658% | |
| 9.1764% | |
| 10.0605% | |
| 11.2596% | |
| 12.8961% | |
| 10.1366% | |
| 10.8499% | |
| 11.9817% | |
| 19.2455% | |
| 14.3771% | |
| 10.418% | |
| 16.015% | |
| 14.574% | |
| 14.9499% | |
| 20.3297% | |
| 14.6922% | |
| 28.3151% | |
| 46.5273% | |
| 51.3185% | |
| 60.4424% | |
| 49.2007% | |
| 71.2493% | |
| 41.0246% | |
| 260.9275% | |
| 371.7002% | |
| 666.309% | |
| 4,804.3344% | |
| 6,041.5625% | |
| 5,309.2742% | |
| 1,546.8165% | |
| 1,868.5567% | |
| 1,059.4628% | |
| 3,312.5475% | |
| 1,408.5653% | |
| 3,367.6471% | |
| 743.5398% | |
| 1,034.4633% |